Market Cap | 43.11M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -102.07M | Forward P/E | -14.00 | EPS next Y | - | 50D Avg Chg | -25.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -61.00% |
Dividend | N/A | Price/Book | 0.60 | EPS next 5Y | - | 52W High Chg | -96.00% |
Recommedations | 3.00 | Quick Ratio | 3.14 | Shares Outstanding | 38.49M | 52W Low Chg | 32.00% |
Insider Own | 1.81% | ROA | -33.09% | Shares Float | 20.63M | Beta | 0.45 |
Inst Own | 65.68% | ROE | -86.14% | Shares Shorted/Prior | 379.63K/513.39K | Price | 1.12 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 960,855 | Target Price | 4.00 |
Oper. Margin | - | Earnings Date | May 12 | Volume | 716,440 | Change | -4.27% |
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
Empire Asset Management | Sell | Aug 27, 19 |
Goldman Sachs | Neutral | Jan 2, 18 |
Cowen & Co. | Outperform | Jan 2, 18 |
Jefferies | Buy | Jan 2, 18 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
EcoR1 Capital, LLC | 10% Owner 10% Owner | Dec 01 | Buy | 1.66 | 185,941 | 308,662 | 5,701,669 | 12/10/21 |
EcoR1 Capital, LLC | 10% Owner 10% Owner | Dec 01 | Sell | 1.67 | 5,887,610 | 9,832,309 | 12/10/21 | |
Davis Aaron I. | Director Director | Nov 17 | Sell | 2.02 | 1,200,000 | 2,424,000 | 4,607,086 | 11/19/21 |
Boxer Capital, LLC | Director Director | Nov 17 | Sell | 1.99 | 1,000,000 | 1,990,000 | 4,607,086 | 11/19/21 |
- | - - | Dec 30 | Buy | 17.16 | 400,000 | 6,864,000 | 5,607,086 | 12/30/20 |
Davis Aaron I. | Director Director | Dec 30 | Buy | 17.16 | 400,000 | 6,864,000 | 5,607,086 | 12/30/20 |